Klin Onkol 2021; 34(1): 69-72. DOI: 10.48095/ccko202169.
Background: The management of metastatic castration-resistant prostate cancer involves second-generation antiandrogen therapy, including enzalutamide. The recommended dose of 160 mg/day is sometimes difficult to use in elderly patients because of the burden of comorbidities. The usefulness of a low effective dose remains unclear. Methods: We report the first ever patient, now aged 87 years, who had progressing prostate cancer and was treated at 25% of the recommended dose for over 4 years. Results: The most striking observation is that nothing extraordinary happened. The disease responded without dramatic toxicities. His follow-up has been serene on both aspects of prostate cancer and general health. Conclusion: Cautious dosage can have a long-lasting favorable impact in the elderly patient.
